Preventive effects of sulphasalazine on colorectal carcinogenesis in mice with ulcerative colitis

In Vivo. May-Jun 2000;14(3):463-6.


Sulphasalazine has been used in the treatment of ulcerative colitis and is known to be a prodrug and split into sulphapyridine and 5-aminosalicylic acid by bacteria in the colon. An increased incidence of colorectal carcinoma is known to occur in patients with ulcerative colitis, which displays a recurrence-remission cycle on colorectal mucosa, i.e., the ulceration and regeneration periods of the colorectal mucosa. Repeated mucosal necrosis-regeneration sequence in chronic ulcerative colitis induced with 3% dextran sulfate sodium led to colorectal carcinogenesis in azoxymethane-pretreated mice. Additive treatment with sulphasalazine normalized the enlarged organs, i.e. liver, spleen and kidney and anemia and leucocytosis induced with 3% dextran sulfate sodium resulted in the reduction of tumorous regions with high-grade dysplasia.

MeSH terms

  • Animals
  • Body Weight
  • Colitis, Ulcerative / drug therapy*
  • Colorectal Neoplasms / prevention & control*
  • Female
  • Gastrointestinal Agents / therapeutic use*
  • Mice
  • Mice, Inbred CBA
  • Organ Size
  • Sulfasalazine / therapeutic use*


  • Gastrointestinal Agents
  • Sulfasalazine